脾体积缩小是肽受体放射性核素治疗中长期白细胞减少风险的可靠独立生物标志物
本研究回顾性分析88例接受177Lu-DOTATATE治疗的不可切除转移性神经内分泌肿瘤患者,评估脾脏照射与白细胞减少的关系。结果显示,治疗后12个月脾体积缩小30%最能准确预测24个月时发生白细胞减少(AUC 0.91,灵敏度0.93,特异度0.90),优于传统实验室参数。
要点
- 治疗后12个月脾体积缩小30%可预测24个月白细胞减少,AUC 0.91。
- 脾体积自动评估预测白细胞减少优于传统实验室参数。
- 绝对和相对白细胞计数及相对脾体积缩小为独立预测因子。
核心结论
- 自动脾体积评估对接受177Lu-DOTATATE治疗患者发生白细胞减少的预测能力优于传统实验室参数。
- 脾体积缩小是预测放射性白细胞减少的有价值、常规可获取的定量影像生物标志物,提示可用于风险评估和管理的潜在临床应用。
研究设计与样本
- 回顾性分析2009年2月至2021年7月在本机构接受177Lu-DOTATATE治疗的88例组织学确诊、不可切除转移性神经内分泌肿瘤患者的血计数和影像数据。
- 纳入标准为基线受体显像肿瘤摄取等于或大于肝脏;排除随访不足24个月、接受少于4个治疗周期、随访期间接受额外治疗或输血的患者。
主要发现
- 绝对和相对白细胞计数及相对脾体积缩小是24个月时放射性白细胞减少的独立预测因子。
- 治疗后12个月脾体积缩小30%最能准确预测24个月时发生白细胞减少,受试者工作特征曲线下面积为0.91,灵敏度为0.93,特异度为0.90,远优于所有其他参数。
关键数值与推荐
- 治疗后12个月脾体积缩小30%预测24个月白细胞减少:AUC 0.91,灵敏度0.93,特异度0.90。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors, despite its dose-limiting hematotoxicity. Herein, the significance of off-target splenic irradiation is unknown. Our study aims to identify predictive markers of peptide receptor radionuclide therapy-induced leukopenia. Methods: We retrospectively analyzed blood counts and imaging data of 88 patients with histologically confirmed, unresectable metastatic neuroendocrine tumors who received 177Lu-DOTATATE treatment at our institution from February 2009 to July 2021. Inclusion criterium was a tumor uptake equivalent to or greater than that in the liver on baseline receptor imaging. We excluded patients with less than 24 mo of follow-up and those patients who received fewer than 4 treatment cycles, additional therapies, or blood transfusions during follow-up. Results: Our study revealed absolute and relative white blood cell counts and relative spleen volume reduction as independent predictors of radiation-induced leukopenia at 24 mo. However, a 30% decline in spleen volume 12 mo after treatment most accurately predicted patients proceeding to leukopenia at 24 mo (receiver operating characteristic area under the curve of 0.91, sensitivity of 0.93, and specificity of 0.90), outperforming all other parameters by far. Conclusion: Automated splenic volume assessments demonstrated superior predictive capabilities for the development of leukopenia in patients undergoing 177Lu-DOTATATE treatment compared with conventional laboratory parameters. The reduction in spleen size proves to be a valuable, routinely available, and quantitative imaging-based biomarker for predicting radiation-induced leukopenia. This suggests potential clinical applications for risk assessment and management.
引用
- Steinhelfer L, Jungmann F, Endrös L, et al. Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy. J Nucl Med. 2024. PMID: 38991748. doi:10.2967/jnumed.123.267098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。